LEDIFOS LEDIPASVIR AND SOFOSBUVIR TABLETS

Get a Price/Quote

MOQ : 1 Bottle

LEDIFOS LEDIPASVIR AND SOFOSBUVIR TABLETS Specification

Storage
Store below 30C, protect from moisture

Expiration Date
24-36 months from date of manufacture

Pacakaging (Quantity Per Box)
28 Tablets (1 tablet per strip, 28 strips per box)

Dosage Form
Tablet

Indication
Chronic hepatitis C infection (genotype 1, 4, 5, and 6)

CAS No
1256388-51-8 (Ledipasvir), 1190307-88-0 (Sofosbuvir)

Salt Composition
Ledipasvir 90 mg and Sofosbuvir 400 mg

Usage
For the treatment of chronic hepatitis C virus (HCV) infection

Grade
Pharmaceutical Grade

Assay
>= 99% (by HPLC)

Molecular Formula
Ledipasvir (C49H54F2N8O6), Sofosbuvir (C22H29FN3O9P)

Origin of Medicine
India

Appearance
Film-coated tablets

Dosage
90 mg Ledipasvir/400 mg Sofosbuvir

Medicine Type
Allopathic

Brand Name
LEDIFOS

Color
Yellow

Therapeutic Class
Antiviral

Packing Type
Bottle

Warning
To be sold by retail on the prescription of Hepatologist / Gastroenterologist / Infectious Disease Specialist only.

Prescription/Non Prescription
Prescription

Marketed By
Hetero Healthcare Ltd.

Route of Administration
Oral

LEDIFOS LEDIPASVIR AND SOFOSBUVIR TABLETS Trade Information

Minimum Order Quantity
1 Bottle

Packaging Details
PACK OF 28 TABLETS

Main Domestic Market
All India

About LEDIFOS LEDIPASVIR AND SOFOSBUVIR TABLETS

PRODUCT DETAILS

BRAND NAME: LEDIFOS
CONTENT: LEDIPASVIR & SOFOSBUVIR
STRENGTH: 400MG + 90MG
PACKAGING: PACK OF 28 TABLETS
MANUFACTURED BY:GLENMARK

Note :-Ledifos Is A Prescription Drug And Should Be Used UnderProper Medical Guidance And Advice. Do Not Share The Medicine With Others,Since They May Be Suffering From A Problem That Is Not Effectively Treated ByThis Drug............

Advanced Therapy for Chronic Hepatitis C

LEDIFOS is a highly effective allopathic antiviral medication developed for the management of chronic hepatitis C infection. With its dual active ingredients, Ledipasvir and Sofosbuvir, LEDIFOS targets multiple genotypes, offering broad therapeutic coverage. The carefully selected dosage and pharmaceutical-grade formulation ensure reliable results and reduce viral loads effectively over prescribed treatment cycles.

Convenient and Controlled Oral Dosage

Each LEDIFOS tablet combines 90 mg of Ledipasvir with 400 mg of Sofosbuvir in a yellow, film-coated form, simplifying daily administration. Supplied in tightly sealed bottles containing 28 tablets, the product ensures precise dosing and lasts for a full treatment cycle. Patients are instructed to follow the regimen exactly as prescribed, and regular medical supervision is crucial throughout therapy.

FAQs of LEDIFOS LEDIPASVIR AND SOFOSBUVIR TABLETS:

Q: How should LEDIFOS tablets be administered for optimal results?

A: LEDIFOS tablets are intended for oral administration and should be taken once daily, as directed by a qualified specialist. Its crucial not to deviate from the prescribed regimen and to consult your hepatologist, gastroenterologist, or infectious disease specialist before making any changes.

Q: What is the therapeutic benefit of using LEDIFOS for hepatitis C?

A: LEDIFOS combines Ledipasvir and Sofosbuvir, which disrupt the replication of the hepatitis C virus. This dual-action mechanism significantly lowers viral loads and enhances the opportunity for sustained virologic response in patients with chronic HCV (genotypes 1, 4, 5, and 6).

Q: When is LEDIFOS prescribed, and who can authorize its use?

A: LEDIFOS is prescribed exclusively for the treatment of chronic hepatitis C virus infection in adults, specifically for genotypes 1, 4, 5, and 6. Only qualified specialistshepatologists, gastroenterologists, or infectious disease expertsare authorized to prescribe this medication.

Q: Where can LEDIFOS be stored to maintain its efficacy?

A: LEDIFOS tablets should be stored below 30C, in a secure, moisture-free environment. Always keep the bottle tightly closed and away from direct sunlight or damp areas to preserve tablet effectiveness throughout the shelf life.

Q: What is the process for obtaining and using LEDIFOS?

A: Patients must consult a relevant medical specialist for evaluation and prescription of LEDIFOS. Upon prescription, the product is dispensed in bottles containing 28 tablets, and the patient must follow the prescribed dosage and schedule under close medical supervision for best therapeutic outcomes.

Q: Are there any precautions associated with LEDIFOS treatment?

A: Yes, LEDIFOS is a prescription medicine intended for use only under specialist supervision. Self-medication is strongly discouraged; adherence to instructed dosage and monitoring for possible side effects are imperative during the course of treatment.

Q: What is the expected shelf life of LEDIFOS tablets?

A: LEDIFOS tablets typically have an expiration period of 24 to 36 months from the date of manufacture. It is important to check expiration dates before use and not consume tablets beyond this period.

Tell us about your requirement